title: [Overexpression of eIF4E gene in acute myeloid leukemia and its relation with disease progression].
abstract: The aim of this study was to detect the expression level of eIF4E gene in patients with non-treated, remission and non-remission/relapse acute myeloid leukemia (AML), and other non-malignant haematologic diseases so as to analyze and reveal the relationship of eIF4E gene expression with AML progression. SYBR Green I RT-PCR was used to assay the expression level of eIF4E mRNA extracted from bone marrow mononuclear cells in 30 patients with AML (6 in M2, 5 in M3, 8 in M4, 10 in M5, 1 in M6) and 20 patients with non-malignant hematologic diseases. The β2-microglubin(β2M) was used as internal reference and the formula 2(-ΔCt)×100% was applied to calculate the expression level of eIF4E gene. The results showed that the eIF4E expression level (7.098 ± 5.544)% in patients with non-treated and non-remitted/relapsed AML was significantly higher than that in patients with remission (0.964 ± 0.312)% (P < 0.01) and non-malignant hematologic diseases (0.248 ± 0.163)% (P < 0.01). There was no difference between latter two group patients, even though the expression level of eIF4E gene in patients with M4 and M5 was higher. As compared with non-malignant hematologic diseases, the expression level of eIF4E gene of patients with remission patients showed no significant difference. It is concluded that the over-expression of eIF4E gene has been found in patients with AML, and its level obviously decreases along with remission of disease, thus the eIF4E gene may be a surveillance parameter for disease progression.
authors.affiliation: Department of Hematology, Affiliated First Hospital, Jinan University, Guangdong Province, China.
authors.forename: Yin-Di
authors.initials: YD
authors.lastname: Jiang
authors.forename: Yu-Hong
authors.initials: YH
authors.lastname: Lu
authors.forename: Shao-Hua
authors.initials: SH
authors.lastname: Chen
authors.forename: Kang-Er
authors.initials: KE
authors.lastname: Zhu
authors.forename: Xue-Li
authors.initials: XL
authors.lastname: Zhang
authors.forename: Zhi
authors.initials: Z
authors.lastname: Yu
authors.forename: Jun
authors.initials: J
authors.lastname: Zhong
authors.forename: Tao
authors.initials: T
authors.lastname: Zhang
authors.forename: Geng-Xin
authors.initials: GX
authors.lastname: Luo
authors.forename: Jie
authors.initials: J
authors.lastname: Chen
authors.forename: Huan-Yu
authors.initials: HY
authors.lastname: Pan
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Lian-An
authors.initials: LA
authors.lastname: Qin
authors.forename: Yang-Qiu
authors.initials: YQ
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D018450:Disease Progression; D039561:Eukaryotic Initiation Factor-4E / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D060888:Real-Time Polymerase Chain Reaction; D055815:Young Adult
chemical_list: D039561:Eukaryotic Initiation Factor-4E